{"url_path":"/sec/ibo/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 EXHIBITS**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1834105/0001493152-26-022512-index.html","accession_number":"0001493152-26-022512","cik":"0001834105","ticker":"IBO","issuer_name":"IMPACT BIOMEDICAL INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1834105/0001493152-26-022512-index.html","primary_entity_key":"0001834105","primary_entity_name":"IMPACT BIOMEDICAL INC."},"word_count":1545,"has_tables":true,"body_markdown":"**ITEM\n6 - EXHIBITS**\n\n \n\n**Exhibit\nNumber**\n** **\n**Exhibit\nDescription**\n\n \n \n \n\n1.1\n \n[Form of Underwriting Agreement between the Company and Aegis Capital Corp. incorporated by reference to Exhibit 1.1 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-275062) filed with the SEC on November 21, 2023.](https://www.sec.gov/Archives/edgar/data/1834105/000149315223042218/ex1-1.htm)\n\n \n \n \n\n3.1\n \n[Amended and Restated Articles of Incorporation of Impact BioMedical Inc. dated July 29, 2020 incorporated by reference to Exhibit 3.1 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-275062) filed with the SEC on November 21, 2023.](https://www.sec.gov/Archives/edgar/data/1834105/000149315223037534/ex3-1.htm)\n\n \n \n \n\n3.2\n \n[Certificate of Amendment to the Amended and Restated Articles of Incorporation of Impact BioMedical Inc. incorporated by reference to Exhibit 3.2 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-275062) filed with the SEC on November 21, 2023.](https://www.sec.gov/Archives/edgar/data/1834105/000149315223037534/ex3-2.htm)\n\n \n \n \n\n3.3\n \n[Certificate of Amendment to the Amended and Restated Articles of Incorporation of Impact BioMedical Inc. incorporated by reference to Exhibit 3.3 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-275062) filed with the SEC on November 21, 2023.](https://www.sec.gov/Archives/edgar/data/1834105/000149315223037534/ex3-3.htm)\n\n \n \n \n\n3.4\n \n[Certificate of Amendment to the Amended and Restated Articles of Incorporation of Impact BioMedical Inc. incorporated by reference to Exhibit 3.4 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-275062) filed with the SEC on November 21, 2023.](https://www.sec.gov/Archives/edgar/data/1834105/000149315223037534/ex3-4.htm)\n\n \n \n \n\n3.5\n \n[Bylaws of the Company incorporated by reference to Exhibit 3.5 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-275062) filed with the SEC on November 21, 2023.](https://www.sec.gov/Archives/edgar/data/1834105/000149315223037534/ex3-5.htm)\n\n \n \n \n\n3.6\n \n[Certificate of Designation of Series A Convertible Preferred Stock incorporated by reference to Exhibit 3.6 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-275062) filed with the SEC on November 21, 2023.](https://www.sec.gov/Archives/edgar/data/1834105/000149315223042218/ex3-6.htm)\n\n \n \n \n\n4.1\n \n[Form of Underwriter Warrant incorporated by reference to Exhibit 4.1 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-275062) filed with the SEC on November 21, 2023.](https://www.sec.gov/Archives/edgar/data/1834105/000149315223042218/ex4-1.htm)\n\n \n \n \n\n10.1\n \n[Share Exchange Agreement dated as of April 27, 2020, among Document Security Systems, Inc., DSS BioHealth Security, Inc., Singapore Development Limited and Global BioMedical Pte Ltd. incorporated by reference to Exhibit 10.1 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-275062) filed with the SEC on November 21, 2023.](https://www.sec.gov/Archives/edgar/data/1834105/000149315223037534/ex10-1.htm)\n\n \n \n \n\n10.2\n \n[Subscription Agreement dated December 19, 2020, between the Company and BioMed Technologies Asia Pacific Holdings Limited incorporated by reference to Exhibit 10.2 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-275062) filed with the SEC on November 21, 2023.](https://www.sec.gov/Archives/edgar/data/1834105/000149315223037534/ex10-2.htm)\n\n \n \n \n\n10.3\n \n[Promissory Note with Dustin Michael Crum dated February 21, 2021 incorporated by reference to Exhibit 10.3 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-275062) filed with the SEC on November 21, 2023.](https://www.sec.gov/Archives/edgar/data/1834105/000149315223037534/ex10-3.htm)\n\n \n \n \n\n10.4\n \n[Stock Purchase Agreement dated March 15, 2021 between the Company and Vivacitas Oncology Inc. incorporated by reference to Exhibit 10.4 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-275062) filed with the SEC on November 21, 2023.](https://www.sec.gov/Archives/edgar/data/1834105/000149315223037534/ex10-4.htm)\n\n \n \n \n\n10.5\n \n[Convertible Promissory Note dated May 14, 2021 incorporated by reference to Exhibit 10.5 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-275062) filed with the SEC on November 21, 2023.](https://www.sec.gov/Archives/edgar/data/1834105/000149315223037534/ex10-5.htm)\n\n \n\n22\n\n[Table of Contents](#toc_001)\n\n \n\n10.6\n \n[Revolving Promissory Note dated December 31, 2020 incorporated by reference to Exhibit 10.6 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-275062) filed with the SEC on November 21, 2023.](https://www.sec.gov/Archives/edgar/data/1834105/000149315223037534/ex10-6.htm)\n\n \n \n \n\n10.7\n \n[Royalty Agreement by and between Global BioLife Inc. and Chemia Corporation, dated August 15, 2018 incorporated by reference to Exhibit 10.7 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-275062) filed with the SEC on November 21, 2023.](https://www.sec.gov/Archives/edgar/data/1834105/000149315223037534/ex10-7.htm)\n\n \n \n \n\n10.8\n \n[Addendum to Royalty Agreement by and between Global BioLife Inc. and Chemia Corporation, dated November 27, 2018 incorporated by reference to Exhibit 10.8 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-275062 ) filed with the SEC on November 21, 2023.](https://www.sec.gov/Archives/edgar/data/1834105/000149315223037534/ex10-8.htm)\n\n \n \n \n\n10.9\n \n[Distribution Agreement by and between BioMed Technologies Asia Pacific Holdings Limited and Impact BioMedical Inc., dated December 9, 2020 incorporated by reference to Exhibit 10.9 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-275062) filed with the SEC on November 21, 2023.](https://www.sec.gov/Archives/edgar/data/1834105/000149315223037534/ex10-9.htm)\n\n \n \n \n\n10.10\n \n[Global BioLife, Inc. Stockholders’ Agreement among Global BioLife, Inc., Global BioMedical, Inc., Holista Colltech Limited, and GRDG Sciences, LLC, dated April 26, 2017 incorporated by reference to Exhibit 10.10 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-275062) filed with the SEC on November 21, 2023.](https://www.sec.gov/Archives/edgar/data/1834105/000149315223037534/ex10-10.htm)\n\n \n \n \n\n10.11\n \n[Amendment No. 1 to Global BioLife, Inc. Stockholders’ Agreement among Global BioLife, Inc., Global BioMedical, Inc., Holista Colltech Limited, and GRDG Sciences, LLC, dated May 22, 2018 incorporated by reference to Exhibit 10.11 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-275062) filed with the SEC on November 21, 2023.](https://www.sec.gov/Archives/edgar/data/1834105/000149315223037534/ex10-11.htm)\n\n \n \n \n\n10.12\n \n[Amendment No. 2 to Global BioLife, Inc. Stockholders’ Agreement among Global BioLife, Inc., Global BioMedical, Inc., Holista Colltech Limited, and GRDG Sciences, LLC, dated August 2020 incorporated by reference to Exhibit 10.12 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-275062) filed with the SEC on November 21, 2023.](https://www.sec.gov/Archives/edgar/data/1834105/000149315223037534/ex10-12.htm)\n\n \n \n \n\n10.13\n \n[Impact BioLife Science, Inc. Stockholders Agreement among Impact BioLife Science, Inc., Impact BioMedical Inc. and GRDG Sciences, LLC, dated December 11, 2020 incorporated by reference to Exhibit 10.13 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-275062) filed with the SEC on November 21, 2023.](https://www.sec.gov/Archives/edgar/data/1834105/000149315223037534/ex10-13.htm)\n\n \n \n \n\n10.14\n \n[Licensing Proceeds Distribution Agreement with GRDG Sciences, LLC dated May 16, 2022 incorporated by reference to Exhibit 10.14 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-275062) filed with the SEC on November 21, 2023.](https://www.sec.gov/Archives/edgar/data/1834105/000149315223037534/ex10-14.htm)\n\n \n \n \n\n10.15\n \n[Amendment No. 1 to Revolving Promissory Note dated December 31, 2021 incorporated by reference to Exhibit 10.15 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-275062) filed with the SEC on November 21, 2023.](https://www.sec.gov/Archives/edgar/data/1834105/000149315223037534/ex10-15.htm)\n\n \n \n \n\n10.16\n \n[Amendment No. 2 to Revolving Promissory Note dated March 31, 2022 incorporated by reference to Exhibit 10.16 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-275062) filed with the SEC on November 21, 2023.](https://www.sec.gov/Archives/edgar/data/1834105/000149315223037534/ex10-16.htm)\n\n \n \n \n\n10.17\n \n[License Agreement with ProPhase Labs, Inc. dated March 17, 2022 incorporated by reference to Exhibit 10.17 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-275062) filed with the SEC on November 21, 2023.](https://www.sec.gov/Archives/edgar/data/1834105/000149315223037534/ex10-17.htm)\n\n \n \n \n\n10.18\n \n[License Agreement with ProPhase Labs, Inc. dated July 18, 2022 incorporated by reference to Exhibit 10.18 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-275062) filed with the SEC on November 21, 2023.](https://www.sec.gov/Archives/edgar/data/1834105/000149315223037534/ex10-18.htm)\n\n \n \n \n\n10.19\n \n[Licensing Proceeds Distribution Agreement with GRDG Sciences, LLC dated February 15, 2022 incorporated by reference to Exhibit 10.19 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-275062) filed with the SEC on November 21, 2023.](https://www.sec.gov/Archives/edgar/data/1834105/000149315223037534/ex10-19.htm)\n\n \n \n \n\n10.20\n \n[Share Exchange Agreement between Impact BioMedical Inc. and DSS BioHealth Security, Inc. incorporated by reference to Exhibit 10.20 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-275062) filed with the SEC on November 21, 2023.](https://www.sec.gov/Archives/edgar/data/1834105/000149315223042218/ex10-20.htm)\n\n \n \n \n\n10.21\n \n[Amendment to Promissory Note effective January 18, 2024 between Impact BioMedical Inc. and DSS, Inc. incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (Commission File No. 333-253037) filed with the SEC on January 22, 2024.](https://www.sec.gov/Archives/edgar/data/1834105/000149315224003318/ex10-1.htm)\n\n \n\n23\n\n[Table of Contents](#toc_001)\n\n \n\n14.1\n \n[Impact BioMedical Employee Handbook incorporated by reference to Exhibit 14.1 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-275062) filed with the SEC on November 21, 2023.](https://www.sec.gov/Archives/edgar/data/1834105/000149315223042218/ex14-1.htm)\n\n \n \n \n\n16.1\n \n[Letter from Turner Stone & Company LLP incorporated by reference to Exhibit 16.1 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-275062) filed with the SEC on November 21, 2023.](https://www.sec.gov/Archives/edgar/data/1834105/000149315223042218/ex16-1.htm)\n\n \n \n \n\n21.1\n \n[List of subsidiaries of Impact BioMedical Inc.](ex21-1.htm)\n\n \n \n \n\n23.2\n \n[Consent of Grassi & Co., CPAs, P.C. incorporated by reference to Exhibit 23.2 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-275062) filed with the SEC on November 21, 2023.](https://www.sec.gov/Archives/edgar/data/1834105/000149315223042218/ex23-2.htm)\n\n \n \n \n\n31.1\n \n[Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act, as amended.](ex31-1.htm)\n\n \n \n \n\n31.2\n \n[Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act, as amended.](ex31-2.htm)\n\n \n \n \n\n32.1\n \n[Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rules 13a-14(b) or 15d-14(b) of the Securities and Exchange Act, as amended, and 18 U.S.C. Section 1350.](ex32-1.htm)\n\n \n \n \n\n101.INS\n \nInline XBRL Instance Document\n\n \n \n \n\n101.SCH\n \nInline XBRL Taxonomy Extension Schema Document\n\n \n \n \n\n101.CAL\n \nInline XBRL Taxonomy Extension Calculation Linkbase\nDocument\n\n \n \n \n\n101.DEF\n \nInline XBRL Taxonomy Extension Definition Linkbase\nDocument\n\n \n \n \n\n101.LAB\n \nInline XBRL Taxonomy Extension Label Linkbase Document\n\n \n \n \n\n101.PRE\n \nInline XBRL Taxonomy Extension Presentation Linkbase\nDocument\n\n \n \n \n\n104\n \nCover Page Interactive Data File (embedded within the\nInline XBRL document)\n\n \n\n24\n\n[Table of Contents](#toc_001)\n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned thereunto duly authorized.\n\n \n\n \n**IMPACT\nBIOMEDICAL, INC.**\n\n \n \n \n\nMay 12, 2026\nBy:\n\n*/s/\nFrank D. Heuszel*\n\n  \n \nFrank\nD. Heuszel\n\n \n \nChief\nExecutive Officer\n\n \n \n(Principal\nExecutive Officer)\n\n \n\nMay 12, 2026\nBy:\n*/s/\nTodd D. Macko*\n\n \n \nTodd D. Macko\n\n \n \nChief Financial Officer\n\n \n \n(Principal Financial\nand Accounting Officer)\n\n \n\n25"}